Enlivex Story

<div class='circular--portrait' style='background:#9CBEFD;color: #ffffff;font-size:4em;'>ET</div>
ENLV -- USA Stock  

USD 12.43  0.82  6.19%

Given the investment horizon of 90 days, Enlivex Therapeutics is expected to generate 8.77 times more return on investment than the market. However, the company is 8.77 times more volatile than its market benchmark. It trades about 0.21 of its potential returns per unit of risk. The DOW is currently generating roughly 0.13 per unit of risk. While some risk-seeking sophisticated investors are getting worried about healthcare space, it is reasonable to focus on Enlivex Therapeutics as a possible investment alternative. We will evaluate if Enlivex Therapeutics' current volatility will continue into November.
Published over two weeks ago
View all stories for Enlivex Therapeutics | View All Stories
Still holding on to Enlivex (NASDAQ:ENLV) given latest volatility fall?
This firm currently holds 359 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the firm is not taking enough advantage from borrowing. The company has a current ratio of 6.71, suggesting that it is liquid enough and is able to pay its financial obligations when due. Enlivex Therapeutics holds a performance score of 14 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.0662, which means not very significant fluctuations relative to the market. Let's try to break down what Enlivex's beta means in this case. As returns on the market increase, Enlivex Therapeutics returns are expected to increase less than the market. However, during the bear market, the loss on holding Enlivex Therapeutics will be expected to be smaller as well. Although it is essential to pay attention to Enlivex Therapeutics historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy towards predicting future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Enlivex Therapeutics expected return of 1.87 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Enlivex Therapeutics treynor ratio, as well as the relationship between the expected short fall and day median price to analyze future returns on Enlivex Therapeutics.
Volatility is a rate at which the price of Enlivex Therapeutics or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Enlivex Therapeutics may increase or decrease. In other words, similar to Enlivex's beta indicator, it measures the risk of Enlivex Therapeutics and helps estimate the fluctuations that may happen in a short period of time. So if prices of Enlivex Therapeutics fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.

How important is Enlivex Therapeutics's Liquidity

Enlivex Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Enlivex Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Enlivex Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Enlivex Therapeutics's total debt and its cash.

How Enlivex utilizes its cash?

To perform a cash flow analysis of Enlivex Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Enlivex Therapeutics is receiving and how much cash it distributes out in a given period. The Enlivex Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Enlivex Therapeutics Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Enlivex Therapeutics reported Net Cash Flow from Operations of (7.04 Million) in 2019

Enlivex Therapeutics Volatility Drivers

Enlivex Therapeutics unsystematic risk is unique to Enlivex Therapeutics and usually not directly affected by the market or economic environment. An example of unsystematic risk is the possibility of poor earnings or a layoff due to coronavirus. One may mitigate nonsystematic risk by buying different securities in the same industry or by buying in different sectors. For example, if you have a position in Enlivex Therapeutics you can also buy DiaMedica Therapeutics. You can also mitigate this risk by investing in the biotechnology sector as well as in companies having nothing to do with it. This type of risk is also called diversifiable risk and can be understood from analyzing Enlivex Therapeutics important indicators over time. Here we run a correlation analysis between relevant fundamental ratios over at least ten year period to find a relationship in the way they react to changes in Enlivex Therapeutics income statement and balance sheet. Here are more details about Enlivex volatility.
Click cells to compare fundamentals   

Another angle On Enlivex Therapeutics

The latest price climb of Enlivex Therapeutics could raise concerns from sophisticated investors as the firm it trading at a share price of 14.30 on slow start in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in November. The stock standard deviation of daily returns for 30 days investing horizon is currently 8.85. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Enlivex Therapeutics partners.

Our take on today Enlivex Therapeutics climb

The potential upside is down to 8.83 as of today. Enlivex Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Enlivex Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Enlivex Therapeutics volatility.

The Current Takeaway on Enlivex Therapeutics Investment

While many other companies under the biotechnology industry are still a bit expensive, Enlivex Therapeutics may offer a potential longer-term growth to sophisticated investors. To summarize, as of the 5th of October 2020, we believe that Enlivex Therapeutics is currently undervalued with below average probability of distress in the next two years. Our overall 30 days 'Buy-Sell' recommendation on the venture is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Enlivex Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com